April 29 - Breakingviews columnists discuss the U.S. drug giant’s hankering for AstraZeneca and whether more so-called inversion deals will follow suit.
01:21
01:25
01:07
01:14
02:00
01:26
01:51
01:05
01:59
01:00
01:12
01:08
02:22
02:48
01:14
01:30
01:14
02:05
00:37
01:51
01:51
01:37
02:22
02:22
01:07
01:14
01:33
01:02
02:16
02:19
01:18
01:35
01:29
01:28
01:40
01:12
01:03
01:43
02:09
01:42
01:14
02:00
01:26
01:05
01:08
00:19
00:42
01:06
00:24
00:24
00:44
01:47
01:07
00:21
01:17
00:56
01:05
01:34
00:50
01:34
01:19
01:22
01:37
03:57
01:24
00:56
01:52
01:39
00:55
00:54
01:07
01:27
02:34
05:33
01:30
01:16
01:04
01:10
01:02
02:59
02:17
00:45
01:48
01:35
01:06
01:46
02:20
01:01
01:13
01:10
01:00
01:50
01:03
01:55
01:47
02:04
01:23
03:24
01:39
00:23
02:27
02:27
01:30
01:51
01:43
01:07
00:44
02:27
01:29
00:52
02:00
02:00
01:04
01:19
00:47
01:26
01:13
01:22
01:22
01:15